On August 19, 2026, a status update was recorded for a clinical trial evaluating CRN04894 related to corticotropin, titled "A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome." The trial, registered as NCT05804669, is listed as Phase 1/Phase 2.
The current status is active, not recruiting. This means the study is ongoing but is no longer enrolling new participants at this time.
The trial is designed to evaluate safety and pharmacokinetics of CRN04894 in the context of Cushing's Syndrome. No results have been reported as part of this update. The study status reflects only the current stage of the trial process, not any outcome or finding.
Further details on the trial protocol and design are available through the official registry listing. Readers can consult the compound overview for additional context on corticotropin.</body_markdown>
<parameter name="sources">["https://clinicaltrials.gov/study/NCT05804669"]